Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine Tumors

Christos Toumpanakis\textsuperscript{a} Michelle K. Kim\textsuperscript{b} Anja Rinke\textsuperscript{c} Deidi S. Bergestuen\textsuperscript{d} Christina Thirlwell\textsuperscript{a} Mohid S. Khan\textsuperscript{a} Ramon Salazar\textsuperscript{e} Kjell Oberg\textsuperscript{f}

\textsuperscript{a}Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK; \textsuperscript{b}Department of Gastroenterology, Mount Sinai School of Medicine, New York, N.Y., USA; \textsuperscript{c}Department of Gastroenterology, Philipps University Marburg, Marburg, Germany; \textsuperscript{d}Department of Gastroenterology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; \textsuperscript{e}Department of Oncology, Institut Catal\`{a} d’Oncologia, Barcelona, Spain; \textsuperscript{f}Department of Endocrine Oncology, University Hospital, Uppsala, Sweden

Abstract

Molecular imaging modalities exploit aspects of neuroendocrine tumors (NET) pathophysiology for both diagnostic imaging and therapeutic purposes. The characteristic metabolic pathways of NET determine which tracers are useful for their visualization. In this review, we summarize the diagnostic value of all available molecular imaging studies, present data about their use in daily practice in NET centers globally, and finally make recommendations about the appropriate use of those modalities in specific clinical scenarios. Somatostatin receptor scintigraphy (SRS) continues to have a central role in the diagnostic workup of patients with NET, as it is also widely available. However, and despite the lack of prospective randomized studies, many NET experts predict that Gallium-68 (\textsuperscript{68}Ga)-DOTA positron emission tomography (PET) techniques may replace SRS in the future, not only because of their technical advantages, but also because they are superior in patients with small-volume disease, in patients with skeletal metastases, and in those with occult primary tumors. Carbon-11 (\textsuperscript{11}C)-5-hydroxy-L-tryptophan (5-HTP) PET and \textsuperscript{18}F-dihydroxyphenylalanine (\textsuperscript{18}F-DOPA) PET are new molecular imaging techniques of limited availability, and based on retrospective data, their sensitivities seem to be inferior to that of \textsuperscript{68}Ga-DOTA PET. Glucagon-like-peptide-1 (GLP-1) receptor imaging seems promising for localization of the primary in benign insulinomas, but is currently available only in a few centers. Fluorine-18 (\textsuperscript{18}F)-fluorodeoxyglucose (\textsuperscript{18}F-FDG) PET was initially thought to be of limited value in NET, due to their usually slow-growing nature. However, according to subsequent data, \textsuperscript{18}F-FDG PET is particularly helpful for visualizing the more aggressive NET, such as poorly differentiated neuroendocrine carcinomas, and well-differentiated tumors with Ki67 values >10%. According to limited data, \textsuperscript{18}F-FDG-avid tumor lesions, even in slow-growing NET, may indicate a more aggressive disease course. When a secondary malignancy has already been established or is strongly suspected, combining molecular imaging techniques (e.g. \textsuperscript{18}F-FDG PET and \textsuperscript{68}Ga-DOTA PET) takes advantage of the diverse avidities of different tumor types to differentiate lesions of different origins. All the above-mentioned molecular imaging studies should always be reviewed and interpreted in a multidisciplinary (tumor board) meeting in combination with the conventional cross-sectional imaging, as the latter remains the imaging of choice for the evaluation of treatment response and disease follow-up.

Key Words

Gastroenteropancreatic neuroendocrine tumors · Molecular imaging · Somatostatin receptor scintigraphy · Positron emission tomography

© 2014 S. Karger AG, Basel
Introduction

Neuroendocrine tumors (NET) represent a very heterogeneous group of neoplasms despite having a shared origin from neuroendocrine cells. Although they are characterized by relatively slow tumor growth, they have malignant potential and, in fact, many of them are diagnosed only after distant metastases have developed. The primary tumor is most commonly located in the gastrointestinal (GI) tract or the pancreas, in which case the tumors are collectively referred to as gastrointestinal-pancreatic (GEP)-NET. These tumors comprise approximately 2% of all malignancies of the GEP system [1]. GEP-NET can be functioning, in which case they are associated with a clinical syndrome caused by hormone release and are named according to the hormone they secrete, or non-functioning, in which case they have all the histological features of NET but are not associated with a specific clinical syndrome related to hormone hypersecretion.

A common feature of most GEP-NET is their high expression of somatostatin receptors, which has proven to be very important for their management. Five different, G-protein-coupled somatostatin receptor subtypes (SSTR-1 to -5) have been cloned and pharmacologically characterized. Among these receptors, SSTR-2 is expressed in approximately 90% of GI-NET and in almost 80% of pancreatic NET (pNET). Exceptions are the insulin-producing pNET (known as insulinomas), in which <50% express SSTR-2. Other SSTRs are also expressed in GEP-NET, but to a much lesser extent [2].

According to the recently revised histopathological classification of the World Health Organization (WHO), the following groups of GEP-NET have been recognised: (1) well-differentiated NET and (2) poorly differentiated neuroendocrine carcinomas (NEC). The latter group has aggressive behavior, similar to common cancers. Also, on the basis of mitotic count and the Ki67 proliferation index, well-differentiated GEP-NET are graded either as G1 (with a mitotic count <2/10 high-power fields and/or Ki67 <2%) or G2 (with a mitotic count 2–20/10 high-power fields and/or Ki67 2–20%). All poorly differentiated NEC are G3 (with a mitotic count >20/10 high-power fields and/or Ki67 >20%) [3].

The diagnosis of GEP-NET is based upon: (1) clinical features, especially in functioning tumors, (2) levels, in blood and urine, of several peptides and amines produced by the tumor (biomarkers), (3) localization of the primary and/or metastatic lesions as determined by imaging studies, and (4) histopathologic confirmation from biopsy or surgical specimen, which represents the ‘gold standard’ for diagnosis and should be obtained whenever possible [4].

Many different imaging techniques are used to localize GEP-NET. Cross-sectional (anatomical) imaging modalities, such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) have been used to localize primary lesions and to stage the extent of the disease. In addition, endoscopic techniques, such as endoscopic ultrasound, have been used with great success to identify lesions that may otherwise have been missed on imaging modalities [5].

Molecular (functional) imaging studies, which are based on NET pathophysiology and especially the presence of SSTR-2 and SSTR-5, have proven superior to standard anatomic imaging in terms of more accurate disease staging and selection of eligible patients for certain treatments. Somatostatin receptor scintigraphy (SRS) is the most established functional imaging for NET worldwide, although its value may be limited by several factors, such as its relatively low resolution for small tumors and background binding in normal tissues. It seems that those limitations have been overcome recently by the introduction of newer analogs and chelators [such as DOTA-[Tyr3]-octreotide (TOC)] suitable as tracers for positron emission tomography (PET) imaging. Also, traditional PET scanning using fluorine-18-fluorodeoxyglucose PET (18F-FDG PET) could be useful in NET with higher Ki67 [6]. Many studies are investigating whether those new imaging modalities alone or in combination are able to provide more precise information about disease extent, patients’ response to treatment, and disease course, taking into account the heterogeneity of NET.

In this review, we summarize the available molecular imaging studies and present data for newer techniques of imaging GEP-NET. We also report on the current use of molecular imaging in NET centers globally, evaluating data gathered by questionnaire. Finally, we recommend the techniques most appropriate in specific clinical scenarios.

Methods

An electronic literature search of the PubMed database was performed using the following search terms: ‘somatostatin receptor scintigraphy’ (Title/Abstract), ‘OctreoScan’ (Title/Abstract), ‘[123]I MIBG’ (Title/Abstract), ‘PET scan’ (Title/Abstract), ‘FDG-PET’ (Title/Abstract), ‘[68]Gallium-PET’ (Title/Abstract), ‘neuroendocrine tumor’ (Title/Abstract), and ‘carcinoid’ (Title/Abstract). Only full articles published in peer-reviewed journals and in English were included.

A Web-based survey was constructed comprising of 14 questions with multiple choice answers, gathering information on: (1)
the local availability of biomarkers and molecular imaging studies, (2) the choice of appropriate diagnostic modalities for different types of NET, and (3) intervals for follow-up assessments. It was administered via e-mail to representatives from 103 specialist NET centers around the world over a 6-week period (response rate of <80% follow-up).

The Oxford Centre for Evidence-Based Medicine’s levels of evidence (May 2001; table 1) were used to evaluate the evidence for (1) our recommendations for specific clinical scenarios and (2) our proposed algorithm [7].

Table 1. Oxford Centre for Evidence-Based Medicine: levels of evidence and grades of recommendation

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Grades of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a SR (with homogeneity) of RCTs</td>
<td>A Consistent level 1 studies</td>
</tr>
<tr>
<td>1b Individual RCT (with narrow CI)</td>
<td>B Consistent level 2 or 3 studies or extrapolations from level 1 studies</td>
</tr>
<tr>
<td>1c All or none</td>
<td>C Level 4 studies or extrapolations from level 2 or 3 studies</td>
</tr>
<tr>
<td>2a SR (with homogeneity) of cohort studies</td>
<td>D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level</td>
</tr>
<tr>
<td>2b Individual cohort study (including low-quality RCT, e.g. &lt;80% follow-up)</td>
<td></td>
</tr>
<tr>
<td>2c ‘Outcomes’ research; ecological studies</td>
<td></td>
</tr>
<tr>
<td>3a SR (with homogeneity) of case-control studies</td>
<td></td>
</tr>
<tr>
<td>3b Individual case-control study</td>
<td></td>
</tr>
<tr>
<td>4 Case series (and poor-quality cohort and case-control studies)</td>
<td></td>
</tr>
<tr>
<td>5 Expert opinion without explicit critical appraisal, or based on physiology, bench research, or ‘first principles’</td>
<td></td>
</tr>
</tbody>
</table>

SR = Systemic review; RCT = randomized control trial.

Overview of Available Molecular Imaging Techniques

Somatostatin Receptor Scintigraphy

SRS has been a bulwark in the diagnosis of NET since the 1990s. SRS is based on the affinity of radiolabeled somatostatin analogs for SSTR. The most commonly used tracer is indium-[111In]-diethylenetriaminepenta-acetic acid (DTPA)-octreotide, also known as [111In]-pentetreotide, which binds specifically to SSTR-2. The tracer has a half-life of 68 h, allowing for imaging at 24 and 48 h. Currently, SRS remains the first-choice imaging modality for the localization of primary tumors and metastases from GEP-NET. It can also be used to predict responses to treatment with somatostatin analogs and to select patients for peptide receptor radionuclide treatment (PRRT) [8].

The overall sensitivity of SRS for NET is reported to be 89%. The technique is particularly useful for the detection of small intestinal NET, for which the reported sensitivity is 86–95% [6]. The overall sensitivity for pNET ranges from 60 to 90% [9]. Combining SRS and single-photon emission CT (SPECT) to give fusion images allows function to be correlated with anatomic location [8]. The sensitivity of SRS is lower in (1) lesions <1 cm, as they are beyond its resolution [10], (2) insulinomas (estimated sensitivity <50%), likely due to the reduced expression of SSTR-2 in these pNET [6], and (3) well-differentiated NET with a proliferation index (Ki67) >10% [11]. SRS sensitivity is particularly limited in poorly differentiated NEC [11].

Other somatostatin analogs with different affinities for SSTR are under investigation. These include technetium (Tc)-labeled compounds, which cost less, are more readily available, and allow faster tumor visualization (with a maximum uptake at 1 h after infusion) compared with In-labeled compounds [8]. The 99mTc-labeled somatostatin analogs researched to date include 99mTc-depreotide, which binds to SSTR-2, -3, and -5 with high affinity [12, 13], and 99mTc-vapreotide, which binds to SSTR-2 and -5 with high affinity, and to SSTR-3 and -4 with moderate affinity [8]. 99mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-TOC and 99mTc-HYNIC-[Tyr3, Thr8]-octreotide (TATE) have been used to image GEP-NET, with similar success to 111In-pentetreotide in the localization of somatostatin-expressing tumors [14–16]. Iodine-123 ([123I])-labeled vasoactive intestinal peptide has also been evaluated; however, this tracer, which binds SSTR-3, has shown lower sensitivity than 111In-pentetreotide for gastrinomas and glucagonomas [8].

123I-Metaiodobenzyl-Guanidine Scintigraphy

123I-metaiodobenzyl-guanidine (MIBG) is an analog of guanethidine, which is taken up by the cell membranes of sympathomedullary tissues and then further stored in catecholamine storage vesicles. 123I-MIBG scintigraphy is the first choice for imaging of functional pheochromocytomas, paragangliomas, and neuroblastomas [8]. However, 123I-MIBG scintigraphy is not routinely recommended in the diagnostic workup of patients with GEP-NET because it has a much lower sensitivity than SRS in the imaging of small-bowel NETs (52 vs. 89%, respectively), and its sensitivity in pNET is only 9% [17]. A complementary role is appropriate, however, to assess the feasibility of treatment with 131I-MIBG.
PET represents an excellent clinical tool in oncology with its generally high sensitivity and resolution. PET allows for whole-body scanning and quantification of tracer uptake. It provides metabolic images based on metabolic variations between normal and malignant cells.

**18F-FDG PET**

18F-FDG PET is extremely important in general oncologic imaging, as it detects the increased glucose metabolism of cancer cells. Although 18F-FDG PET has not been as useful for the imaging of well-differentiated GEP-NET with low proliferation indices, it does play an important role in more aggressive tumors [8]. Binderup et al. [9] have shown that 18F-FDG PET has a sensitivity of 92% for the detection of NET with a proliferation index of >15%, compared with 69% for SRS. Also, in a series of 18 NET patients with Ki-67 >10%, 18F-FDG PET detected more, the same as, and fewer tumor lesions than SRS in 78, 6, and 17% of patients, respectively [10]. The role of 18F-FDG PET for predicting treatment response was highlighted in a recent study which included G1 or G2 advanced NET, as none of the 18F-FDG PET-negative patients had progressed at the first follow-up examination after 177Lu-DOTA-TATE PRRT. In that study population, G2 NET and 18F-FDG PET positivity were frequently associated with more aggressive disease course [11]. Finally, it seems that avid uptake in 18F-FDG PET predicts survival. In a prospective study enrolling 98 NET patients, univariate analysis showed that a 18F-FDG PET maximal standardized uptake value (SUVmax) of >9 and a high Ki67 index were significant predictors of overall survival, with hazard ratios (HR) of 8.8 (95% CI: 2.7–28.7) and 2.6 (95% CI: 1.3–5.1), respectively [12]. The role of 18F-FDG PET for predicting treatment response was highlighted in a recent study which included G1 or G2 advanced NET, as none of the 18F-FDG PET-negative patients had progressed at the first follow-up examination after 177Lu-DOTA-TATE PRRT. In that study population, G2 NET and 18F-FDG PET positivity were frequently associated with more aggressive disease course [11]. Finally, it seems that avid uptake in 18F-FDG PET predicts survival. In a prospective study enrolling 98 NET patients, univariate analysis showed that a 18F-FDG PET maximal standardized uptake value (SUVmax) of >9 and a high Ki67 index were significant predictors of overall survival, with hazard ratios (HR) of 8.8 (95% CI: 2.7–28.7) and 2.6 (95% CI: 1.3–5.1), respectively [12]. The role of 18F-FDG PET for predicting treatment response was highlighted in a recent study which included G1 or G2 advanced NET, as none of the 18F-FDG PET-negative patients had progressed at the first follow-up examination after 177Lu-DOTA-TATE PRRT. In that study population, G2 NET and 18F-FDG PET positivity were frequently associated with more aggressive disease course [11]. Finally, it seems that avid uptake in 18F-FDG PET predicts survival. In a prospective study enrolling 98 NET patients, univariate analysis showed that a 18F-FDG PET maximal standardized uptake value (SUVmax) of >9 and a high Ki67 index were significant predictors of overall survival, with hazard ratios (HR) of 8.8 (95% CI: 2.7–28.7) and 2.6 (95% CI: 1.3–5.1), respectively [12].

**Carbon-11-5-Hydroxy-L-Tryptophan PET and 18F-Dihydroxyphenylalanine PET**

The knowledge that NET take up and decarboxylate amine precursors has led to the development of carbon-11 (11C)-5-hydroxy-L-tryptophan (5-HTP) PET and 18F-dihydroxyphenylalanine (DOPA) PET [10, 20]. 11C-5-HTP PET is more effective in the detection of NET than both CT and SRS, and may be particularly useful in detecting small tumors and early recurrences. On the other hand, 18F-DOPA PET performs better than SRS in carcinoids, but not in noncarcinoid NET [10]. One study compared 11C-5-HTP PET and 18F-DOPA PET in patients with GI-NET and pNET. For GI-NET, 18F-DOPA PET was found to be more sensitive than 11C-5-HTP PET (98 vs. 89%, respectively), while the opposite was noted for patients with pNET (80 vs. 96%, respectively) [21]. A limitation of 11C-5HTP PET is the need for a cyclotron to produce the required isotope [10]. Thus, this technique is available in only a few centers worldwide.

**Gallium-68 (68Ga) PET**

Gallium-68 (68Ga)-1,4,7,10 Tetraazacyclododecane,1,4,7,10 DOTA-Conjugated Peptides PET

Imaging with 68Ga-labeled somatostatin analogs provides some advantages over SRS imaging, and has therefore recently become more popular. 68Ga has a short half-life of 68 min, allowing imaging after only 1 h and completion within 2–3 h, in contrast to the 24–48 h required for SRS [10]. With a higher affinity for NET than 111In-pentetreotide, 68Ga is a generator-produced positron that does not need a cyclotron. Moreover, 68Ga gives better spatial resolution than SRS-SPECT [9]. Finally, the effective dose is less than half of the dose provided by 111In-DTPA-OCT [22].

Multiple peptides have been used with in conjunction with 68Ga. Somatostatin analogs such as DOTA-TOC, DOTA-TATE, and DOTA-[Nal3]-octreotide (NOC) have recently been used with PET imaging. They demonstrate differing affinity profiles for the SSTR subtypes: 68Ga DOTA-TATE has high affinity for SSTR-2, 68Ga DOTA-TOC for SSTR-2 and -5, and 68Ga DOTA-NOC for SSTR-2, -3, and -5 [23].

According to the results of a recent meta-analysis that included 16 studies, the pooled sensitivity and specificity of 68Ga-DOTA PET were 93 and 91%, respectively [24]. False-negative results are mainly associated with very small lesions (<7 mm), which are beyond the resolution of PET, and with tumors with low SSTR expression, such as poorly differentiated NEC and insulinomas. However, two key facts need to be taken into account when interpreting these imaging studies: (1) inflammatory diseases can be associated with false-positive results and (2) 68Ga-DOTA PET uptake in the uncinate process of the pancreas, the adrenal gland, and accessory spleens can be physiologic [25, 26].

In recent years, 68Ga-DOTA PET studies have not only aided in the diagnosis and localization of tumors but also in determining the most appropriate management of NET [27–29]. Hofman et al. [27] investigated the impact of 68Ga-DOTA-TATE compared with 111In-octreotide in the management of a series of 59 NET patients. The impact was high, leading to a change in modality (e.g. from surgery to chemotherapy) in 47% of patients.
68 Ga-DOTA-TATE PET (fig. 1) seems to be superior to 18F-FDG PET in the detection of G1- and G2-grade NET, with median SUV_max values for 68 Ga-DOTA-TATE PET of 29 and 15.5, respectively, compared with values for 18F-FDG PET of 2.9 and 10.5. In contrast, there is a much higher uptake of 18F-FDG than 68 Ga-DOTA-TATE in high-grade (G3) NET (SUV_max of 11.7 for FDG vs. 4.4 for DOTA-TATE) [26]. Only one small study has compared 68 Ga-DOTA-NOC with 18F-DOPA directly; in this study, 68 Ga-DOTA-NOC revealed more lesions and more occult primary tumors [27]. Compared with CT, 68 Ga-DOTA-NOC PET has demonstrated a higher sensitivity (80 vs. 100%, respectively) and specificity (98 vs. 100%) in the detection of NET bone metastases [30]. Finally, Kabasakal et al. [31] compared 68 Ga-DOTA-TATE and 68 Ga-DOTA-NOC in the same NET patient group. Both tracers demonstrated physiologic uptake in SSTR-2-expressing organs (e.g. pituitary, salivary, thyroid, and prostate glands), but the physiologic uptake in pituitary and salivary glands was much higher for 68 Ga-DOTA-TATE than 68 Ga-DOTA-NOC. Although the tracers seem to have similar diagnostic accuracy, 68 Ga-DOTA-TATE seems to provide a significantly higher lesion uptake than 68 Ga-DOTA-NOC [31].

**Novel Imaging Techniques**

A number of new agents are currently under investigation. In a study by Gotthardt et al. [32], for example, positive gastrin receptor scintigraphy results were obtained in GEP-NET patients with negative 111In-labeled SRS. One preclinical study assessed 68 Ga-DOTA-minigastrin (MG0) for the detection of cholecystokinin-2 (CCK2)/gastrin receptor-positive tumors in a murine model [33]. This study took advantage of the binding of radiolabeled minigastrin to the CCK2/gastrin receptor, which is expressed on the majority of NET and medullary thyroid carcinomas. High receptor affinity was demonstrated with 68 Ga-DOTA-MG0, with appropriate blockade upon administration of competing peptides. Tumors expressing the CCK2/gastrin receptor were then visualized with small-animal PET imaging. This study demonstrates that 68 Ga-DOTA-MG0 is a promising tracer for use with PET imaging in humans with CCK2/gastrin receptor-positive tumors [33]. Based on the fact that glucagon-like peptide-1 (GLP-1) receptors are expressed in high density in almost all benign insulinomas, Wild et al. [34] demonstrated for the first time the superiority of GLP-1 receptor SPECT/CT scans, using 111In-labeled [Lys40(Ahx-DTPA)NH2]-exendin-4 as a tracer. The same group of authors confirmed those encouraging results, using the same 111In-labelled GLP-1 receptor agonist, in 6 patients with benign insulinomas [35]. On the contrary, they showed that GLP-1 imaging has limited sensitivity in malignant insulinomas, where SSTR-2 receptor imaging studies seem to be superior [36]. Recently, Sowa-Staszczak et al. [37] demonstrated 100% sensitivity and specificity in similar patients, with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4. The authors of this study suggest that the GLP-1 receptor tracer labelled with 99mTc instead of 111In is characterized by the general availability of the isotope, lower radiation exposure to patients and staff, and potential usefulness of this compound for intraoperative localization of insulinoma foci using a gamma probe. Finally, this promising diagnostic method seems to have some therapeutic implications as well. Wicki et al. [38] treated a transgenic mouse model of human insulinoma using [Lys40(Ahx-DTPA-111In)NH2]-exendin-4. No significant acute organ toxicity was noted, while the tumor volume decreased up to 94%.

The sensitivity of all available molecular imaging techniques in well-differentiated G1 and G2 NET is summarized in table 2 [6, 9, 17, 21, 24].
Results of the International Survey

In total, completed questionnaires were received from 72 centers. The majority of participating NET centers were European (68%), with the others located in the USA, South America, and Israel. Due to the large number of responses from Spanish centers (26 centers) compared to the rest of Europe (23 centers), each survey item was analyzed for differences between these two subgroup responses using χ² or Fisher’s exact test with Bonferroni correction. There were no significant differences in responses.

47% of the centers had >500 patients under their care, while 71% of the Spanish centers had <100 patients under their care compared to 22% in the rest of Europe. Based on the previously noted statistical methods, no significant differences in responses between centers with >500 patients versus centers with <500 patients were noted.

Most NET centers have access to SRS and ¹⁸F-FDG-PET while, as expected, only a small number of NET centers (<20%) have access to ¹⁸F-DOPA PET or ⁶⁸Ga-DOTA PET. Although the majority of centers (84%) would include SRS in their initial diagnostic workup, almost 10% would never perform an SRS at the time of diagnosis. The latter centers have regular access to ⁶⁸Ga-DOTA PET and it seems that they prefer this novel imaging modality to SRS. On the contrary, the vast majority of NET centers (89%) that participated in the survey stated that, even if they had all of the molecular imaging techniques available, they would use ¹²³I-MIBG, ¹⁸F-DOPA PET, and ⁶⁸Ga-DOTA PET only in selected patients. However, almost 10% of NET centers would routinely perform ¹⁸F-FDG PET at the time of diagnosis.

Finally, the majority of NET centers (52%) would perform molecular imaging routinely during follow-up.

Recommendations for Specific Clinical Scenarios

Assessment of Patients with Well-Differentiated GEP-NET

SRS can still be considered the molecular imaging technique of choice at diagnosis and follow-up in the majority of patients with well-differentiated GEP-NET (level of evidence 3, grade of recommendation A/B). In patients with negative SRS or equivocal findings, however, ⁶⁸Ga-DOTA-TATE PET, if available, is recommended, as it can identify additional lesions and may therefore influence the way the disease is managed (level of evidence 3, grade of recommendation B) [39]. Although results from a small study discussed previously suggest ¹⁸F-FDG PET can be superior to SRS in well-differentiated NET with Ki67 >10% [11], the routine use of ¹⁸F-FDG PET in these patients cannot be definitely recommended, as more research is needed. However, if ¹⁸F-FDG PET is performed for some reason in well-differentiated NET and is positive, this may indicate a more aggressive disease course. Also, if FDG-PET and SRS have demonstrated uptake in different tumor lesions in the same patient, a heterogeneous NET cell population can be suspected and a repeat biopsy may be considered (level of evidence 5, grade of recommendation D). The routine use of ¹²³I-MIBG scintigraphy cannot be recommended, as it is positive in only 9% of pNET and approximately 50% of small-bowel NET. However, it can be requested in advanced small-bowel NET, when patients are considered as candidates for ¹³¹I-MIBG treatment (level of evidence 3, grade of recommendation C).

Assessment of Patients with Poorly Differentiated NEC

¹⁸F-FDG PET can be considered the first-choice molecular imaging technique in poorly differentiated NEC because SRS is often negative and ⁶⁸Ga-DOTA PET shows only low-grade uptake (level of evidence 3, grade of rec-
ommendation A/B) [8]. In those types of tumors, $^{18}$F-FDG PET can reveal unsuspected tumor lesions, leading clinicians to revise disease management plans, particularly with regards to interventional treatments. However, in poorly differentiated NEC with progressing disease, despite systemic chemotherapy (which is the initial treatment of choice in these patients), and as alternative treatment options are very limited, it is not unreasonable to request an SRS or $^{68}$Ga-labeled PET (level of evidence 5, grade of recommendation D). In the unlikely scenario that these scans show good tracer uptake, the patient may be a candidate for PRRT. There are no accurate factors so far that could predict a positive uptake in SRS or $^{68}$Ga-labeled PET in those tumors.

Assessment of Patients with NET of Unknown Primary Location and Patients with Suspected NET

It is not uncommon for NET to present late in the disease course with evidence of extensive hepatic metastases revealed by conventional cross-sectional imaging (i.e. CT and MRI), but in which the primary tumor cannot be clearly identified. Detection of the primary tumor site is important to optimize the treatment strategy, given that response rates to several treatment options differ for metastatic small-bowel NET and pNET. Although immunohistochemistry in the biopsy specimen from a metastatic lesion could be quite helpful (e.g. serotonin expression most likely indicates a small-bowel primary), the combination of cross-sectional imaging with molecular imaging is equally important towards that direction, as it may also provide information about the anatomic location of the primary lesion. As the sensitivity of SRS is only 39% in patients with advanced NET of unknown primary location [40], new molecular imaging techniques are warranted in this setting. The location of the primary tumor can be visualized with $^{68}$Ga-DOTA-NOC PET in 60% of cases, resulting in amendments to the management plan in 10–15% of patients (level of evidence 3, grade of recommendation A/B) [41]. As malignant insulinomas often express SSTR-2, unlike their benign counterparts, they can also be revealed with $^{68}$Ga-DOTA-TATE PET [36]. For solitary benign insulinomas, GLP-1 receptor imaging represents an important emerging diagnostic tool (level of evidence 4, grade of recommendation C) [35]. In patients in whom clinical, biochemical, or radiologic findings raise the suspicion of an NET, $^{68}$Ga-DOTA-peptide PET should be used with caution. According to a recent study, $^{68}$Ga-DOTA-NOC PET gave true positives in approximately 13% of cases with suspicious lesions in conventional imaging, in 10% of cases with relevant symptoms/signs, and in only 1.5% of cases for whom an NET was suspected based on abnormal biomarkers [42].

Patients with Documented/Suspected Secondary Malignancies

According to recent epidemiologic data, approximately 22% of patients with NET develop other malignancies [43]. Such secondary malignancies are more likely when the primary NET is in the small bowel, and they are more likely to occur synchronously than metachronously. The suspicion for a second malignancy is usually raised on follow-up cross-sectional imaging (CT/MRI) either because the new lesion(s) have non-NET radiological appearances or have an unusually rapid rate of progression for NET (level of evidence 5, grade of recommendation C). Concomitant use of $^{18}$F-FDG PET and more specific molecular imaging for well-differentiated NETs, such as $^{68}$Ga-DOTA-TATE, may facilitate the identification of the origin of metastatic lesions (level of evidence 4, grade of recommendation C; fig. 2). Indeed, Desai et al. [44] reported an interesting case in which molecular imaging was used to differentiate hepatic metastases originating from colorectal cancer and hepatic metastases originating from an NET in the same patient. An $^{18}$F-FDG PET is therefore recommended for NET patients who develop new indeterminate tumor lesions with cross-sectional imaging whenever there is a past medical history of a second malignancy or when a second primary is suspected (level of evidence 4, grade of recommendation C). In such cases, $^{18}$F-FDG PET should be compared with either SRS or $^{68}$Ga-DOTA PET, as well as with patient’s cross-sectional imaging in the multidisciplinary team meeting, and if necessary a biopsy of the new suspicion lesion may be arranged (level of evidence 5, grade of recommendation D).

Molecular Imaging before and after PRRT

Patients who are considered candidates for PRRT should first undergo SRS to confirm avid tracer uptake by the tumor lesions (level of evidence 3, grade of recommendation A/B). In cases of well-differentiated NET with negative SRS, $^{68}$Ga-DOTA PET should still be performed, as it may independently demonstrate good uptake. $^{68}$Ga-DOTA PET is also valuable in the evaluation of receptor status before PRRT, as it can determine the receptor density semiquantitatively by the measurement of SUV (level of evidence 3, grade of recommendation C). In the study noted earlier [39], $^{68}$Ga-DOTA-TATE PET was positive in 74% of tumor lesions for which SRS was nega-
Fig. 2. $^{18}$F-FDG PET and $^{68}$Ga-DOTA-TATE PET in a patient with a history of Meckel’s diverticulum NET and colorectal cancer. a $^{18}$F-FDG PET showing avid uptake in 2 colorectal cancer metastases (confirmed histopathologically, posthepatectomy, red arrows). b $^{68}$Ga DOTA-TATE PET of the same patient showing avid uptake in Meckel’s diverticulum NET, mesenteric node and with segment 2 NET liver metastasis (green arrows), but no uptake in colorectal liver metastases which appear photopenic (blue arrows).
tive or equivocal; consequently, 39% of patients were considered suitable for PRRT. Treatment responses did not differ between patients for whom $^{68}$Ga-DOTA-TATE PET was positive but SRS negative and patients who had PRRT following a positive SRS. As tumor responses following PRRT should always be evaluated with cross-sectional imaging following completion of treatment course, there are no clear recommendations regarding the routine use of either SRS or $^{68}$Ga-DOTA PET for this purpose. However, there are some preliminary data suggesting that SUV$_{\text{max}}$ can be used to discriminate between a partial response and stable disease (level of evidence 4, grade of recommendation C) [26].

On the basis of the above, proposed imaging algorithms for advanced intestinal and pNET (also including benign insulinoma, as an exception) are presented in figures 3 and 4, respectively.

**Conclusions**

SRS continues to have a central role in the diagnostic workup of patients with GEP-NET. It is available in the majority of NET centers worldwide, and almost all NET specialists request SRS as part of the initial assessment of patients. However, its limited sensitivity in small tumor lesions, insulinomas, and poorly differentiated NEC needs to be taken into account.

$^{18}$F-FDG PET is particularly helpful for visualizing more aggressive NET, such as poorly differentiated NEC, and well-differentiated tumors with Ki67 values >10%. Limited data so far have shown that $^{18}$F-FDG-avid tumor lesions, even in slow-growing NET, may indicate a more aggressive disease course.

$^{68}$Ga-DOTA PET represents a recent development in NET molecular imaging, which may replace SRS in the...
future, as it has technical advantages over SRS in terms of image quality and patient convenience, and has better sensitivity in patients with small-volume disease, in patients with skeletal metastases, and in those with occult primary tumors. To date, however, there are no prospective randomized studies comparing the two imaging modalities in the same patient population, and $^{68}$Ga-DOTA PET is not widely available.

GLP-1 receptor imaging represents a very promising diagnostic tool for localization of the primary in benign insulinomas; however, it is available only in very limited centers.

$^{11}$C-5-HTP PET and $^{18}$F-DOPA PET are also new molecular imaging techniques for NET. Their availabilities, however, are even more limited than that of $^{68}$Ga-DOTA PET and, based on retrospective data, their sensitivities seem to be inferior to that of $^{68}$Ga-DOTA PET.

Finally, when a secondary malignancy has already been established or is strongly suspected, combining molecular imaging techniques (e.g. FDG PET and $^{68}$Ga-DOTA PET) takes advantage of the diverse avidities of different tumor types to differentiate lesions of different origins.

All the molecular imaging studies discussed above should always be reviewed and interpreted in a multidisciplinary (tumor board) meeting in combination with the conventional cross-sectional imaging, as the latter remains the imaging of choice for evaluation of treatment response and disease follow-up.

**Acknowledgments**

The authors wish to thank the other participants of the Knowledge Network. They would also like to thank the centers that responded to their questionnaire (for a list of the centers that provided their details, see the online supplementary material, www.karger.com/doi/10.1159/000358727).
This article was developed independently by members of a working group of the Knowledge Network. This program involved meetings and collaboration between clinicians working in the field of NET around the world, which was organized and funded by Ipsen. Editing assistance was provided by Watermeadow Medical and funded by Ipsen. The authors were fully responsible for the concept and all content, for all editorial decisions, and for approval of the final version.

References

74

Neuroendocrinology 2014;99:63–74
DOI: 10.1159/000358727


